Explore the words cloud of the RETHRIM project. It provides you a very rough idea of what is the project "RETHRIM" about.
The following table provides information about the project.
Coordinator |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address contact info |
Coordinator Country | Netherlands [NL] |
Project website | http://www.rethrim.eu |
Total cost | 5˙857˙587 € |
EC max contribution | 5˙857˙587 € (100%) |
Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
Code Call | H2020-PHC-2014-single-stage |
Funding Scheme | RIA |
Starting year | 2015 |
Duration (year-month-day) | from 2015-01-01 to 2021-12-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | ACADEMISCH ZIEKENHUIS LEIDEN | NL (LEIDEN) | coordinator | 2˙334˙931.00 |
2 | UNIVERSITAET LEIPZIG | DE (LEIPZIG) | participant | 660˙043.00 |
3 | IMMUNOTOOLS GMBH | DE (Friesoythe) | participant | 534˙025.00 |
4 | FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON | ES (SORIA) | participant | 399˙787.00 |
5 | GenomeScan B.V. | NL (Leiden) | participant | 370˙000.00 |
6 | KATHOLIEKE UNIVERSITEIT LEUVEN | BE (LEUVEN) | participant | 354˙850.00 |
7 | LUNDS UNIVERSITET | SE (LUND) | participant | 333˙200.00 |
8 | OSPEDALE PEDIATRICO BAMBINO GESU | IT (ROMA) | participant | 331˙537.00 |
9 | ERASMUS UNIVERSITEIT ROTTERDAM | NL (ROTTERDAM) | participant | 309˙300.00 |
10 | KAROLINSKA INSTITUTET | SE (STOCKHOLM) | participant | 229˙912.00 |
11 | GENOMIC INVESTMENTS BV | NL (LEIDEN) | participant | 0.00 |
12 | STICHTING HEMATO-ONCOLOGIE VOOR VOLWASSENEN NEDERLAND (HOVON) | NL (Amsterdam) | participant | 0.00 |
Stem cell regenerative therapies hold great promise for patients suffering from a variety of disorders that are associated with tissue or organ injury. Regeneration relies on tissue or organ-specific stem and progenitor cells, but can also aim at promoting the endogenous repair capacity of the body.
Mesenchymal stromal cells (MSC) are undergoing clinical testing in a variety of clinical conditions aiming at repair through direct or indirect mechanisms. Their ability to form bone or cartilage is used to directly repair these tissues. In other conditions their regenerative effects are based on endogenous repair through their anti-inflammatory properties. The latter mechanism is important in the treatment of acute Graft-versus-Host Disease (GvHD). We have been involved in the clinical development from the beginning and we have shown the therapeutic potential. However, no results of controlled randomized phase 3 studies have been published to date, thereby hampering safety and efficacy assessment.
Within our consortium we have developed an academic infrastructure for the harmonized production of MSC. In the RETHRIM proposal this will be combined with our clinical expertise to conduct the first Europe-wide placebo controlled randomized phase III trial using MSC regenerative therapy for the treatment of steroid-resistant visceral GvHD. Central to the RETHRIM project is the clinical trial for which 150 patients will be recruited. All MSC products will be extensively analysed using molecular and functional markers, in order to develop a potency signature for the product and for the prediction of response. We also intend to collect data from additional quality of life, health technology assessment and ethical studies. We will apply for an Orphan Drug Designation in Europe and this may serve as a stepping-stone for the further commercialization of the MSC product, once a positive outcome has been obtained.
Website | Websites, patent fillings, videos etc. | 2020-02-12 08:28:27 |
Take a look to the deliverables list in detail: detailed list of RETHRIM deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2018 |
Frederick W. Thielen, Hedwig M. Blommestein, Liesbeth E.M. Oosten, Friso G. Calkoen, Arjan C. Lankester, Jaap J. Zwaginga, Katarina Le Blanc, Alba Redondo, Fermin Sánchez-Guijo, Mattia Algeri, Franco Locatelli, Wim E. Fibbe, Carin A. Uyl-de Groot Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model published pages: 676-683, ISSN: 0902-4441, DOI: 10.1111/ejh.13158 |
European Journal of Haematology 101/5 | 2020-02-12 |
2016 |
Koen Schepers, Willem E. Fibbe Unraveling mechanisms of mesenchymal stromal cell-mediated immunomodulation through patient monitoring and product characterization published pages: 15-23, ISSN: 0077-8923, DOI: 10.1111/nyas.12984 |
Annals of the New York Academy of Sciences 1370/1 | 2020-02-12 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RETHRIM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RETHRIM" are provided by the European Opendata Portal: CORDIS opendata.